Development Programs Indication Preclinical Phase 1 Phase 2 Phase 3 Status
VK2809 (TRβ Agonist) NASH
60%
Phase 2b VOYAGE trial ongoing
VK2735 (Dual GLP-1/GIP agonist) Obesity
48%
Phase 2 VENTURE study ongoing
VK2735 Oral (Dual GLP-1/GIP agonist) Metabolic disorders
35%
Phase 1 ongoing
VK0214 (TRβ Agonist) X-ALD
35%
Phase 1b ongoing